Protein expression and subcellular localization of familial acute myelogenous leukemia-related factor

Huang,Yuanmao; Chen,Lulu; Ye,Meiling; Lin,Shenglong; Zi,Youmei; Wang,Shaoyuan

doi:10.3892/or.2013.2773

Protein expression and subcellular localization of familial acute myelogenous leukemia-related factor

Authors:
- Yuanmao Huang
- Lulu Chen
- Meiling Ye
- Shenglong Lin
- Youmei Zi
- Shaoyuan Wang
View Affiliations

Affiliations: Union Clinical Medical College, Fujian Medical University, Fuzhou 350001, P.R. China, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, P.R. China
Published online on: October 1, 2013 https://doi.org/10.3892/or.2013.2773
Pages: 2672-2676

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was designed to evaluate the expression and subcellular distribution of the familial acute myelogenous leukemia-related factor (FAMLF). A 14-amino acid epitope of the predicted open reading frame of the FAMLF gene was identified using bioinformatics. This polypeptide was synthesized, conjugated to keyhole limpet hemocyanin and was subsequently used to produce antibodies. The antibody titer and specificity were characterized using ELISA and western blot assays, respectively. The antibody detected FAMLF protein expression in several human leukemia cell lines, bone marrow cells derived from one acute myeloid leukemia patient and one chronic myeloid leukemia patient, but not in bone marrow cells of healthy subjects. The FAMLF/GFP fusion protein was expressed in both the nucleus and the cytoplasm of transfected NIH3T3 cells. Our results demonstrate that the FAMLF gene is expressed in an AML patient but not in healthy controls, suggesting its association with AML.

View Figures

View References

1	Riva L, Luzi L and Pelicci PG: Genomics of acute myeloid leukemia: the next generation. Front Oncol. 2:402012. View Article : Google Scholar : PubMed/NCBI
2	Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA and Bloomfield CD: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 26:5078–5087. 2008. View Article : Google Scholar
3	Schlenk RF, Döhner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A and Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New Engl J Med. 358:1909–1918. 2008. View Article : Google Scholar : PubMed/NCBI
4	Birg F, Courcoul M, Rosnet O, Bardin F, Pebusque MJ, Marchetto S, Tabilio A, Mannoni P and Birnbaum D: Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood. 80:2584–2593. 1992.PubMed/NCBI
5	Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F, Pizzolo G, Larizza L and Morra E: Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 107:3463–3468. 2006.PubMed/NCBI
6	Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK and Linch DC: No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 106:3658–3665. 2005. View Article : Google Scholar
7	Ommen HB, Nyvold CG, Braendstrup K, Andersen BL, Ommen IB, Hasle H, Hokland P and Ostergaard M: Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol. 141:782–791. 2008. View Article : Google Scholar
8	Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B and Bloomfield CD; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115:453–474. 2010. View Article : Google Scholar : PubMed/NCBI
9	O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M and Gregory KM: Acute myeloid leukemia. J Natl Compr Cancer Netw. 10:984–1021. 2012.
10	Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore SD, Levis MJ, Wright JJ, Garrett-Mayer E and Kaufmann SH: Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 11:4841–4852. 2009. View Article : Google Scholar : PubMed/NCBI
11	Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA and Martelli AM: Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells. Cancer Res. 68:9394–9403. 2008. View Article : Google Scholar : PubMed/NCBI
12	Moore J, Seiter K, Kolitz J, Stock W, Giles F, Kalaycio M, Zenk D and Marcucci G: A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res. 30:777–783. 2006. View Article : Google Scholar : PubMed/NCBI
13	Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, Tsunoda S, Matsuo Y, Kirito K, Sato Y, Mano H and Kano Y: Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia. 21:1005–1014. 2007.
14	Zhang YW, Wang SY, Lin X and Wang CY: Identification of differentially expressed genes in familial acute myelogenous leukemia by suppression subtractive hybridization. Zhonghua Yi Xue Za Zhi. 87:533–537. 2007.(In Chinese).
15	Wang CY, Wang SY, Lin X, Zhang YW and Li JG: Full-length cloning of a novel gene, ELF2C, related to familial acute myelo-genous leukemia. Zhonghua Yi Xue Za Zhi. 87:2245–2248. 2007.(In Chinese).
16	Li JG, Wang SY, Huang YM and Wang CY: Full-length cDNA cloning and biological function analysis of a novel gene FAMLF related to familial acute myelogenous leukemia. Zhonghua Yi Xue Za Zhi. 88:2667–2671. 2008.(In Chinese).
17	Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, Babic M, Lin M, Carmagnac A, Lee YK, Kok CH, Gagliardi L, Friend KL, Ekert PG, Butcher CM, Brown AL, Lewis ID, To LB, Timms AE, Storek J, Moore S, Altree M, Escher R, Bardy PG, Suthers GK, D'Andrea RJ, Horwitz MS and Scott HS: Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 43:1012–1017. 2011. View Article : Google Scholar : PubMed/NCBI
18	Holme H, Hossain U, Kirwan M, Walne A, Vulliamy T and Dokal I: Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia. Br J Haematol. 158:242–248. 2012. View Article : Google Scholar : PubMed/NCBI
19	Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, Boissel N, Dhedin N, André JM, Cornillet-Lefebvre P, Baruchel A, Mozziconacci MJ and Sobol H: High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood. 113:5583–5587. 2009. View Article : Google Scholar : PubMed/NCBI
20	Renneville A, Mialou V, Philippe N, Kagialis-Girard S, Biggio V, Zabot MT, Thomas X, Bertrand Y and Preudhomme C: Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia. 23:804–806. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ripperger T, Steinemann D, Göhring G, Finke J, Niemeyer CM, Strahm B and Schlegelberger B: A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation? Leukemia. 23:1364–1366. 2009. View Article : Google Scholar
22	Stelljes M, Corbacioglu A, Schlenk RF, Döhner K, Frühwald MC, Rossig C, Ehlert K, Silling G, Müller-Tidow C, Juergens H, Döhner H, Berdel WE, Kienast J and Koschmieder S: Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein α from hematopoietic cells in a family with AML. Leukemia. 25:1209–1210. 2011.PubMed/NCBI